KDNY — Chinook Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.90bn
- $2.60bn
- $6.13m
Annual cashflow statement for Chinook Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -95.4 | -82.4 | -81.6 | -103 | -188 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 21.1 | 18 | 34.8 | -0.79 | 41.7 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.73 | -3.52 | -8.42 | -5.86 | 19.2 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -68.8 | -65.5 | -55.8 | -103 | -117 |
| Capital Expenditures | -2.37 | -1.26 | -0.797 | -1.88 | -1.65 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 41.8 | -0.503 | 110 | -111 | -98.3 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 39.4 | -1.76 | 110 | -113 | -100 |
| Financing Cash Flow Items | -2.95 | 0.213 | 0.084 | 33.9 | 25.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.5 | 0.743 | 124 | 210 | 151 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -31.3 | -66.7 | 178 | -5.7 | -66.3 |